Multiple Sclerosis - 2/16

Entry	Author	Date	Location
Genzyme-Spinout Peptimmune Files for Chapter 7 Liquidation	Ryan McBride	03/23/11	Boston
RXi Sells Stock and Warrants, Cardiorobotics Raises $6.6M, ImmunoGen Dishes On New Drugs, & More Boston-Area Life Sciences News	Erin Kutz	03/04/11	Boston
FDA Wants More Data on Merck KGaA’s MS Pill As Biogen Develops Rival Therapy	Ryan McBride	03/02/11	Boston
Genzyme, After Months of Holding Out, Agrees to be Sold to Sanofi-Aventis for $20.1B	Ryan McBride	02/16/11	Boston
Biogen Board OK’s 20M Share Buyback	Ryan McBride	02/14/11	Boston
Genzyme-Sanofi Deal Might Be Close, Report Says	Ryan McBride	02/01/11	Boston
Genzyme Lets Sanofi Conduct Due Diligence	Erin Kutz	01/31/11	Boston
European Panel Rejects Biogen MS Drug	Ryan McBride	01/21/11	Boston
Dendreon’s European Plan, Williams Heads East, Allozyne Passes Clinical Trial, & More Seattle-Area Life Sciences News	Luke Timmerman	01/13/11	Seattle
Allozyne Passes First Clinical Trial, Dreams Big About a Once-Monthly Multiple Sclerosis Drug	Luke Timmerman	01/10/11	Seattle
Biogen Idec’s New R&D Boss, Doug Williams, Spurns Corner Office for a Return to Big Science	Luke Timmerman	01/06/11	Boston
Biogen Idec Nabs Doug Williams as R&D Head, Steve Holtzman as BD Chief To Fill Out Management Team	Luke Timmerman	01/05/11	Boston
Biogen Aims to Reduce PML Risk	Ryan McBride	12/22/10	Boston
Allozyne’s Next Drug, Made to Kill Two Birds With One Stone, Being Prepped for Clinic	Luke Timmerman	11/16/10	Seattle
Uncle Sam Delivers $18.4M in Research Awards to Michigan Biotechs	Ryan McBride	11/05/10	Detroit
Biogen Idec Chief Aims to Make Firm More Like Biotech and Less Like Pharma with Restructuring Plan	Ryan McBride	11/04/10	Boston
Biogen Idec Offering Jobs to Quarter of San Diego Workers, While Most Get Layoff Notices	Ryan McBride	11/03/10	Boston
Biogen Idec Axes 650 Jobs, Closes San Diego Site, Bets Future on Neurology	Luke Timmerman	11/03/10	Boston
PacBio IPO, Not Exactly the Netscape Moment of 2010, But a Win for Genomics	Luke Timmerman	10/28/10	San Francisco
Biogen, Genentech Revamp Alliance	Luke Timmerman	10/21/10	San Francisco
FDA Panel Votes Against Arena’s Weight-Loss Drug, ImThera Encouraged by Early Test Results, Novartis Wins FDA Approval for MS Pill, & More San Diego Life Sciences News	Bruce V. Bigelow	09/23/10	San Diego
Biogen Rival Reaches Finish Line with Oral Drug for MS	Ryan McBride	09/22/10	Boston
PerkinElmer Sells Unit for $500M, Aveo Stock Climbs, Pfizer Buys FoldRx, & More Boston-Area Life Sciences News	Erin Kutz	09/03/10	Boston
Biogen Idec Strikes Potential $345M Deal with Knopp to Develop ALS Drug	Ryan McBride	08/18/10	Boston
How Much Would You Pay for Genzyme?	Ryan McBride	07/26/10	Boston
Glaxo’s Tempero Pharma Advances on Hot Niche of Immunology	Ryan McBride	07/15/10	Boston
Allozyne Breaks Silence, Accelerator’s Mini-Golf Hijinks, Maveron’s Vision for Primary Care, & More Seattle-Area Life Sciences News	Luke Timmerman	07/15/10	Seattle
Allozyne, After a Stealthy Year on a Slim Budget, Re-Emerges with MS Drug and Fat Pipeline	Luke Timmerman	07/14/10	Seattle
Arena Signs Deal With Eisai for Lorcaserin, Qualcomm CEO Identifies Two Opportunities in Mobile Health, & More San Diego Life Sciences News	Bruce V. Bigelow	07/08/10	San Diego
New CEO George Scangos Says Biogen Idec’s R&D Has to Improve	Ryan McBride	07/01/10	Boston
Page 2 of 6	« previous page · next page »

Entry

Author

Date

Location

Genzyme-Spinout Peptimmune Files for Chapter 7 Liquidation

03/23/11

RXi Sells Stock and Warrants, Cardiorobotics Raises $6.6M, ImmunoGen Dishes On New Drugs, & More Boston-Area Life Sciences News

Erin Kutz

03/04/11

Boston

FDA Wants More Data on Merck KGaA’s MS Pill As Biogen Develops Rival Therapy

Ryan McBride